Evaluation of efficacy of epinastine hydrochloride ophthalmic solution for allergic conjunctival diseases in the senior persons.

Evaluation of efficacy of epinastine hydrochloride ophthalmic solution for allergic conjunctival diseases in the senior persons. - Evaluation of efficacy of epinastine hydrochloride ophthalmic solution for allergic conjunctival diseases in the senior persons.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012954

Enrollment

Registered

2014-01-31

Start date

2014-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic conjunctivitis

Interventions

Epinastine hydrochloride ophthalmic solution

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a) patients with allergic conjunctival diseases 1)Patients who provided written informed consent for participating in this study. 2)Only the data gathered from MAST-33 positive patients are examined.

Exclusion criteria

Exclusion criteria: Patients who cannot discontinue the drugs that may have an influence on evaluation of drug efficacy, such as steroids, immunosuppression agent.

Design outcomes

Primary

Measure	Time frame
improvement of subjective symptoms improvement of objective finding	—

Secondary

Measure	Time frame
quantitative evaluation of hyperemia	—

Countries

Japan

Contacts

Public ContactTamaki Sumi

Kochi Medical School Department of Ophthalmology

sumitama@kochi-u.ac.jp088-880-2391

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026